** Shares of gene therapy developer Lexeo Therapeutics
rise 13.62% to $8.74 premarket
** Co says reached alignment with FDA on registrational development plan for LX2006 to support an accelerated approval pathway
** LX2006 is being developed as a gene therapy that is delivered intravenously for the treatment of Friedreich's ataxia cardiomyopathy
** Friedreich's ataxia is a genetic multi-system disorder and 80% of patients are estimated to develop cardiomyopathy, a type of heart disease
** LX2006 was granted regenerative medicine advanced therapy (RMAT) designation to accelerate development - LXEO
** Brokerage Stifel says alignment is a big win
** Up to last close, stock down ~42% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。